



**Joint Working Executive Summary**

Published on [www.bayer.co.uk](http://www.bayer.co.uk)

<b>Project title</b>	AF quality improvement project within GP practices across West Yorkshire and Harrogate & Rural Districts
<b>Project partners</b>	<ul style="list-style-type: none"> <li>• Yorkshire and Humber Academic Health Science Network (AHSN)</li> <li>• Bayer plc</li> </ul>
<b>Project summary</b>	<p>Implement at scale a successful quality improvement stroke prevention project. This project aims to address the needs of 40 GP practice populations across West Yorkshire &amp; Harrogate where patients with Atrial Fibrillation that are at moderate to high risk of stroke are identified and managed effectively within primary care to reduce the incidence of AF related stroke. The project will adopt best practice from successful work across the National AHSN network.</p> <p>The main focus of this initiative is to implement an AF focused Quality Improvement (QI) initiative in GP practices. This will support the practices in identifying, reviewing and managing patients which will lead to implementing and sustaining changes.</p>
<b>Expected benefits to patients, the NHS and Bayer</b>	<p><b><u>Patients</u></b></p> <ul style="list-style-type: none"> <li>• Reduce AF related stroke risk by improving anti-coagulation</li> <li>• Increase the numbers of patients with AF who are managed in accordance with NICE guidance</li> </ul> <p><b><u>NHS</u></b></p> <ul style="list-style-type: none"> <li>• Meeting NICE quality standards for the management of atrial fibrillation and adherence to national guidelines for patients requiring anticoagulation</li> <li>• To increase the proportion of patients receiving appropriate anticoagulant therapy through clear guidelines on initiation and discontinuation of therapies as clinically appropriate</li> <li>• To offer anticoagulation therapy to patients who are suitable in line with national NICE and local guidelines</li> <li>• Patients' therapy is optimised with treatment options including, warfarin, LMWHs and Direct Oral Anticoagulants (DOACs) in accordance with the protocols approved by the CCGs</li> </ul> <p><b><u>Bayer</u></b></p> <ul style="list-style-type: none"> <li>• Increasing the number of patients suitable for anticoagulation in line with NICE guidance including DOACs which may include rivaroxaban</li> <li>• Improved reputation as a result of working in partnership to benefit patient outcomes and experience</li> <li>• Develop a deeper insight and understanding of the NHS</li> </ul>
<b>Start date</b>	April 2018

Date of Preparation: April 2018

Job bag number: UKMAC0118003c